Antipsychotic Polypharmacy for Schizophrenia

Introduction to Antipsychotic Polypharmacy

The American Psychiatric Association recommends antipsychotic monotherapy as the gold standard and advises against routine use of combined antipsychotics, with the goal of minimizing side effects and maximizing efficacy 1, 2
At least 20% of patients with schizophrenia do not respond adequately to monotherapy, creating a legitimate clinical need for alternative strategies such as antipsychotic polypharmacy (APP) 2

The World Federation of Societies of Biological Psychiatry acknowledges that combining clozapine with another second-generation antipsychotic may have advantages over monotherapy in treatment-resistant cases, with aripiprazole being a commonly recommended agent 3
The most guideline-supported use of APP is adding a second antipsychotic to augment clozapine when clozapine monotherapy proves ineffective, with therapeutic clozapine plasma levels (≥350 ng/mL) verified for at least 3 months or minimum dose of 500 mg/day 3, 4
Aripiprazole is the most strongly recommended agent to combine with clozapine, as it may reduce residual positive and negative symptoms while potentially improving metabolic side effects, according to the Finnish guidelines 4, 5

Confirm adequate monotherapy trials: At least two different antipsychotics at therapeutic doses for 4-6 weeks each, to ensure that monotherapy has been optimized before considering APP 5
Rule out non-adherence: Consider long-acting injectables or therapeutic drug monitoring before concluding treatment failure, as non-adherence can be a significant factor in apparent treatment resistance 5
Optimize current medication: Ensure therapeutic blood levels and adequate duration before adding a second agent, to minimize the risk of adverse effects and maximize efficacy 4, 5

Mandatory clozapine monitoring continues: Weekly blood counts for first 6 months, then every 2 weeks, to minimize the risk of adverse effects such as agranulocytosis 4
Monitor for extrapyramidal symptoms, particularly akathisia, especially when adding partial D2 agonists like aripiprazole or cariprazine, as these can be significant side effects of APP 4
Cardiovascular monitoring: tachycardia, chest pain, dyspnea, to minimize the risk of cardiovascular adverse effects 4
Metabolic parameters: weight, glucose, lipids at baseline, 3 months, and annually, to monitor for metabolic side effects such as weight gain and dyslipidemia 4, 6

Never use APP as an initial treatment strategy—monotherapy must be optimized first, to minimize the risk of adverse effects and maximize efficacy 6, 5
Don't assume "more is better"—polypharmacy increases adverse effects without proportional efficacy gains in most cases, and should be used judiciously 6
Avoid combining two antipsychotics from the same class without clear justification, as this can increase the risk of adverse effects without providing additional benefits 6
Don't add augmentation before confirming therapeutic drug levels and ruling out non-adherence, to ensure that APP is used only when necessary 5

If APP is initiated: Document baseline symptoms and severity with standardized scales, to monitor for efficacy and adverse effects 5
Schedule reassessment at 4-8 weeks to evaluate response, and adjust treatment as needed to minimize adverse effects and maximize efficacy 5
If stable improvement is achieved, attempt gradual reduction back to monotherapy, to minimize the risk of adverse effects and maximize efficacy 5
If no improvement after adequate trial, discontinue the added agent rather than continuing ineffective polypharmacy, to minimize the risk of adverse effects and maximize efficacy 5

Current guidelines advise against routine use of aripiprazole plus quetiapine in schizophrenia because clinical trials have not demonstrated a significant benefit over quetiapine monotherapy. 7, 8
Both aripiprazole and quetiapine are second‑generation antipsychotics with overlapping receptor profiles, providing no complementary pharmacologic advantage that would justify their combined use. 8

Patients with schizophrenia should undergo at least two trials of different antipsychotic monotherapies at therapeutic doses for a minimum of 4–6 weeks each before any combination therapy is considered. 7, 8
Before declaring a treatment failure, clinicians must verify adherence using long‑acting injectable formulations or therapeutic drug monitoring. 8
If two adequate monotherapy trials fail, clozapine monotherapy is recommended as the evidence‑based treatment for treatment‑resistant schizophrenia. 8

The only antipsychotic combination with evidence of benefit is clozapine plus low‑dose aripiprazole (5–15 mg/day); aripiprazole augmentation can reduce residual psychotic symptoms and mitigate clozapine‑related metabolic side effects. 7, 8
According to NICE guidelines, adding a second antipsychotic to clozapine is permissible only after clozapine monotherapy has proven ineffective, and the added agent should be selected to avoid exacerbating clozapine’s side‑effect profile. 8

Clozapine achieves long‑term symptom control in approximately 70 % of patients with treatment‑resistant schizophrenia. 7
Around 20 % of patients with schizophrenia do not respond adequately to antipsychotic monotherapy, yet adding a second antipsychotic without evidence increases adverse effects without improving outcomes. 7
Initiating antipsychotic polypharmacy as a first‑line strategy is discouraged; monotherapy optimization must precede any combination approach. 8
A second antipsychotic should not be introduced until therapeutic plasma concentrations of the first agent are confirmed and non‑adherence has been excluded. 8

If clinicians choose to use a combination that does not include clozapine, they must document the specific reasons for not attempting clozapine therapy. 8
When a combination is employed, baseline metabolic, extrapyramidal, and cardiovascular parameters should be recorded, and if clinical improvement is observed, a gradual taper back to monotherapy is recommended, as many patients tolerate the transition well. 8